Coronary disease & ACSGuideline or statement
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
- Scientific statement
Recommendations
As issued by the authors
Evidence supports CYP2C19 genetic testing before oral P2Y12 inhibitors are prescribed in ACS or PCI
Precision approach (LOF carriers: ticagrelor or prasugrel; noncarriers: clopidogrel) reduces ischaemic events without increasing bleeding risk, per recent trials and meta-analyses
Original publication
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association. Circulation. Published 20 June 2024. doi:10.1161/cir.0000000000001257
Summarised from the published abstract; every number is checked against it